Bone drug works for breast cancer survivors

	Tweet

Risedronate, better known by the brand name Actonel, is effective for maintaining or improving the bone strength of women who have had chemotherapy for breast cancer, researchers report.

They explain in the Journal of Clinical Oncology that add-on chemotherapy has prolonged survival for women with breast cancer. However, chemotherapy brings on early menopause, which leads to the bone-thinning disease osteoporosis and to bone fractures.

To investigate the usefulness of risedronate in combating these effects, Dr. Susan L. Greenspan of the University of Pittsburgh and colleagues assigned 87 women who had undergone chemotherapy to take risedronate or a placebo once a week.

Many of the women in the study were also taking a so-called aromatase inhibitor such as letrozole to reduce the odds of a cancer relapse, and this made a difference to bone density.

For example, by the end of the 24-month study, women in the placebo group had a significant reduction in bone density of 4.8 percent at the spine and 2.8 percent at the hip if they were on an aromatase inhibitor. Those in the placebo group who were not taking an aromatase inhibitor maintained bone density at the spine, but had a significant 1.2 percent loss at the hip.

For women given risedronate, spine bone density fell by 2.4 percent and remained stable at the hip if they were also taking an aromatase inhibitor. The greatest improvement was seen in women on risedronate who were not taking an aromatase inhibitor: spine bone density rose by 2.1 percent and there was a 2.2 percent increase at the hip.

Risedronate “proved to be effective with or without the use of an aromatase inhibitor,” Greenspan and her colleagues conclude.

Further studies, they add, are needed to see whether these improvements in bone density “translate to fracture reduction for these patients.”

SOURCE: Journal of Clinical Oncology, June 1, 2008.

RELATED STORIES:
Burden of proof: Breast cancer changes fall short   New screening technique could provide more reliable breast cancer detection   Long-term tamoxifen boosts breast cancer survival   Selective Marker Found to Indicate Aggressive Form of Breast Cancer   Smoking increases risk of breast cancer in postmenopausal women   Declining breast cancer incidence in Canada with declining HRT usage   Targeting MMPs to halt advanced metastatic breast cancer   Women well informed about breast cancer, yet lacking knowledge about current treatments   Novel methods for improved breast cancer survival   Fruits And Veggies Don’t Prevent Breast Cancer Recurrence   Wife’s breast cancer hard on some spouses: study   Lymphedema: Risk Reduction and Management Strategies   Cancer cells in blood can identify risk of recurrence in breast cancer   Smoking increased risk of death in women with breast cancer   Breast Cancer Cells Outsmart the Immune System and Thrive   Noninvasive combination technique may reduce number of breast biopsies   Hip size of mothers linked to breast cancer in daughters   Active women with breast cancer may live longer   Novel approach to treating breast cancer shows great promise   Cancer study backs Herceptin with chemo   Pathway Links Inflammation, Angiogenesis and Breast Cancer   Osteo Drug Stops Bone Loss From Breast Cancer Chemo

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]